CLZ 1001
Alternative Names: CLZ-1001; ES-MSSCLatest Information Update: 31 Jul 2023
Price :
$50 *
At a glance
- Originator Cellatoz Therapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Cartilage disorders; Osteoporosis; Periodontal disorders
Most Recent Events
- 25 Jul 2023 Cellatoz Therapeutics and Seoul National University Bundang Hospital agree to co-develop cell therapies
- 25 Jul 2023 Cellatoz has patents pending for method for controlling selective differentiation of musculoskeletal stem cell in South Korea, Europe, China, Australia and Canada
- 24 Jul 2023 CLZ 1001 is available for licensing as of 24 Jul 2023. https://cellatozrx.com/en/